Combining Tarlatamab with Chemo-immunotherapy to Kick-Start a New Era in Small Cell Lung Cancer Treatment
- Tracing the breakthrough journey of tarlatamab from discovery to development, showcasing the scientific insights that enabled a first‑in‑class T‑cell–engager approach for SCLC
- Revealing the synergistic potential of pairing T‑cell engager molecules with checkpoint inhibitors and chemotherapy, supported by compelling preclinical evidence that demonstrates enhanced anti‑tumour activity and immune activation
- Highlighting emerging clinical data on tarlatamab and chemo‑immunotherapy combinations, illustrating how this strategy may unlock deeper, more durable responses for patients with limited treatment options